Physician profile
Mark A Pane
NPI 1801845722
$123,197.82
in general payments reported to CMS, 2019-2025
65 companies · $768 in 2025
The $768 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31K · 2022: $31K · 2023: $43K · 2024: $17K · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $8,316 · Consulting Fee: $670 · Travel and Lodging: $43.23 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,255.00 |
| Food and Beverage | $8,315.99 |
| Consulting Fee | $670.00 |
| Travel and Lodging | $43.23 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $79,798.22 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $12,511.82 | 2021 | |
| Biogen, INC. | $12,020.74 | 2021-2025 | Vumerity, Tysabri, Tecfidera |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,412.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,349.28 | 2021-2024 | Austedo Xr, Austedo |
| Ucb, INC. | $1,336.06 | 2021-2024 | Briviact, Rystiggo, Nayzilam |
| Mallinckrodt Hospital Products INC. | $1,326.06 | 2021-2025 | Acthar |
| Acadia Pharmaceuticals INC | $997.25 | 2021-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $831.53 | 2021-2025 | |
| Celgene Corporation | $814.38 | 2021-2024 | Zeposia |
| Sk Life Science, INC. | $732.04 | 2021-2024 | Xcopri |
| Mdd US Operations, LLC | $708.37 | 2021-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $615.00 | 2021-2024 | Ingrezza, Ongentys |
| Emd Serono, INC. | $597.84 | 2021-2025 | Mavenclad |
| Pfizer INC. | $496.20 | 2021-2024 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.